Recombinant Human CXCR1 Protein，His

CXCR1, a member of the CXC chemokine receptor family, plays a pivotal role in mediating the effects of interleukin-8 (IL-8) and other chemokines involved in inflammatory responses and immune cell trafficking. Its expression is predominantly found in neutrophils and various other immune cells, making it a key player in both innate and adaptive immunity. Research has indicated that CXCR1 is involved in the pathogenesis of several diseases, including cancer, where it influences tumor growth and metastasis through its interaction with the chemokine milieu. The receptor's role in modulating angiogenesis and its contributions to the tumor microenvironment have made it a target of interest in therapeutic research. Recombinant CXCR1 proteins have been produced to better understand its structure-function relationships and to develop potential inhibitors for clinical applications. The development of these recombinant proteins not only facilitates the exploration of CXCR1 signaling pathways but also aids in drug discovery efforts aimed at modifying its activity for therapeutic benefits. Recent advances in biotechnology have enabled the production of high-purity CXCR1 proteins, allowing for more sophisticated binding and functional assays, shedding light on its interactions with ligands and downstream signaling events. This ongoing research is critical for identifying new therapeutic approaches to treat diseases associated with dysfunctional CXCR1 signaling, particularly in oncological contexts and inflammatory disorders. Through these studies, the hope is to elucidate CXCR1's biological functions and leverage this knowledge to design novel interventions targeting CXCR1 for enhanced patient outcomes.